USA flag logo/image

An Official Website of the United States Government

Development of a Personalized Medicine Interface for the Safe and Effective…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
85841
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
HL090055
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PHARMACOGENETICS DIAGNOSTIC LABORATORIES
201 E. JEFFERSON STREET Suite 309 LOUISVILLE, KY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2008
Title: Development of a Personalized Medicine Interface for the Safe and Effective Treat
Agency: HHS
Contract: 2R44HL090055-02
Award Amount: $1,394,314.00
 

Abstract:

DESCRIPTION (provided by applicant): Warfarin is the most commonly used oral anticoagulant medication. Because an individual's proper warfarin dose is difficult to assess, most physicians initiate therapy at a standard dose and follow up with an INR blood test to ensure the medicine is working properly. Unfortunately, therapeutic warfarin doses vary significantly from patient to patient, so that even a standard dose can cause life-threatening hemorrhaging. Genetic and non-genetic factors both influence an individual's warfarin dose requirement and response characteristics, and although the importance of pharmacogenetics to warfarin therapy is understood, clear guidance for how such information should be applied to patient therapy is woefully absent. The Per sonalized Medicine Interface (PerMIT) software utility supplies this critical guidance by modeling the dose requirements and response characteristics of individual patients based on their genotypic and physical characteristics. Using state-of-the-art multi variate computations, PerMIT conveniently calculates a warfarin maintenance dose estimate and models the influence of repeated dosing on plasma drug concentration. PerMIT provides guidance during the transition from induction to maintenance therapy and lim its the potential for misinterpretation of INR measurements by clearly displaying the relationship of the dosing regimen to the progress toward steady-state. The specific aim of Phase I was to develop a computational model that estimates the most appropria te warfarin maintenance dose for an individual, accurately estimates the plasma concentration of S-warfarin following each warfarin dose, and provides a visual estimate of the time to reach steady state. PGXL Laboratories has accomplished this specific aim with the creation of the graphical patient care interface, PerMIT. The specific aim of Phase II is to demonstrate the power of PerMIT in guiding superior clinical management of patients taking warfarin. Three technical objectives will demonstrate that the software functions as intended, that it is user friendly, and that it is clinically effective: (1) Validate the analytical accuracy of computational algorithms which drive the PerMIT module; (2) Drive design improvements through Usability Testing; (3) Mea sure the clinical value of PerMIT in a prospective trial of PerMIT-guided therapy versus standard of care. Completion of the above-stated objectives will: (1) confirm that the computational basis of PerMIT is consistent with the state-of-the-art in warfari n dose estimation and plasma concentration modeling, (2) assure the highest quality user interface based on a validated approach to Usability Testing, and (3) demonstrate the utility of PerMIT for improved efficiency of patient care. PUBLIC HEALTH RELEVAN CE: Warfarin is the most commonly prescribed oral anticoagulant, but managing patients on warfarin is difficult due to variability in patients' response to the medication; indeed, adverse reactions to warfarin are second only to insulin in frequency. Inhe rited differences account for approximately 40% of the variability in warfarin dose response between individuals, but clinicians thus far have had no clear and easy methods or tools to help them understand and account for this variability when directing pa tient therapy. PerMIT:Warfarin provides muchneeded guidance to clinicians throughout the course of warfarin therapy and limits the potential for misinterpretation of blood test results (INR measurements) by clearly displaying the relationship between a pat ient's dosing regimen and their progress toward stable therapy.

Principal Investigator:

Kristen K. Reynolds
5025691584
KRISTEN.REYNOLDS@PGXLAB.COM

Business Contact:


diana.maslowski@pgxlab.com
Small Business Information at Submission:

PHARMACOGENETICS DIAGNOSTIC LABORATORIES
201 E. JEFFERSON STREET Suite 309 LOUISVILLE, KY -

EIN/Tax ID: 134203042
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No